Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-02-19

Clinical Trial Update: Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dolutegravir in HIV-1 infected subjects with resistance to raltegravir and/or elvitegravir; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tivicay (dolutegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-02-19